Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Ahn

Showing results (601-610 of 616) with videos related to

Pageof 62
Sort By:
Clinical Lung Cancer|August 29, 2022
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L StudyMyung J Ahn, Hye R Kim, James C H Yang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2022
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyA Psyrri, J Fayette, K Harrington, et al.
Cell Reports. Medicine|July 31, 2025
Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunityJulie J Ahn, Steven Dudics, David P Langan, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 25, 2015
Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient managementS Huprikar, L Danziger-Isakov, J Ahn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2022
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trialA T C Chan, V H F Lee, R-L Hong, et al.
ESMO Open|September 18, 2025
Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial)S Hwang, M H Hong, S H Shin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH studyF de Marinis, T M Kim, L Bonanno, et al.
Journal of Korean Medical Science|October 20, 2001
Epidemiologic and clinical survey of Behcet's disease in Korea: the first multicenter studyD Bang, J H Lee, E S Lee, et al.
Journal of Medicinal Chemistry|September 18, 2020
Synthesis and Structure-Activity Relationship of Dual-Stage Antimalarial Pyrazolo[3,4-<i>b</i>]pyridinesScott Eagon, Jared T Hammill, Martina Sigal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2022
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancerA Passaro, N Leighl, F Blackhall, et al.
Pageof 62

Showing results (601-610 of 616) with videos related to

Sort By:
Pageof 62
Clinical Lung Cancer|August 29, 2022
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L StudyMyung J Ahn, Hye R Kim, James C H Yang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2022
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyA Psyrri, J Fayette, K Harrington, et al.
Cell Reports. Medicine|July 31, 2025
Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunityJulie J Ahn, Steven Dudics, David P Langan, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 25, 2015
Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient managementS Huprikar, L Danziger-Isakov, J Ahn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2022
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trialA T C Chan, V H F Lee, R-L Hong, et al.
ESMO Open|September 18, 2025
Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial)S Hwang, M H Hong, S H Shin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH studyF de Marinis, T M Kim, L Bonanno, et al.
Journal of Korean Medical Science|October 20, 2001
Epidemiologic and clinical survey of Behcet's disease in Korea: the first multicenter studyD Bang, J H Lee, E S Lee, et al.
Journal of Medicinal Chemistry|September 18, 2020
Synthesis and Structure-Activity Relationship of Dual-Stage Antimalarial Pyrazolo[3,4-<i>b</i>]pyridinesScott Eagon, Jared T Hammill, Martina Sigal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2022
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancerA Passaro, N Leighl, F Blackhall, et al.
Pageof 62